General Dermatology
Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Anti-Aging
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management

Diagnostic challenge

March 1, 2004

Article

Washington - The standard multi-drug therapy for multi-bacillary leprosy (MDT-MB) recommended by the World Health Organization proved effective in treating patients with Lucio's phenomenon, a rare necrotizing reaction sometimes seen in patients with Lucio's leprosy, according to Luna Azulay-Abulafia, assistant professor of dermatology at the Universidade do Estado do Rio de Janeiro and at the Universidade Gama Filho, Brazil. At the February American Academy of Dermatology annual meeting, Dr. Azulay-Abulafia described two cases of Lucio's phenomenon in Brazilian patients with Lucio's leprosy successfully treated with MDT-MB, with no need for systemic therapy with corticosteroids or thalidomide.